Tetramethrin

Summary

Tetramethrin (CHEMBL1788386) is an approved small-molecule pyrethroid ester insecticide (ATC P03BA04); indicated across 1 condition including parasitic infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P03BA04
• Indications: 1 condition
• Chemistry: 331.4 Da · C19H25NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1788386
Name	Tetramethrin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	83975
ChEBI	CHEBI:39397
ATC	P03BA04
Molecular formula	C19H25NO4
Molecular weight	331.4
InChIKey	CXBMCYHAMVGWJQ-UHFFFAOYSA-N

SMILES: CC(=CC1C(C1(C)C)C(=O)OCN2C(=O)C3=C(C2=O)CCCC3)C

IUPAC name: (1,3-dioxo-4,5,6,7-tetrahydroisoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate

Pharmacological roles (ChEBI): pyrethroid ester insecticide.

Also known as: Tetramethrin, Tetramethrine, Tetrametrina, SID50113148, SID144211334, SID170466513, TETRAMETHRIN

Patent coverage: 6,954 distinct patent families (22,736 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
parasitic infectious disease	4	MONDO:0005135	EFO:0001067

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).